Sarah D. Busslinger

Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life

Fabian Brandl, Sarah D. Busslinger, Uwe Zangemeister‐Wittke et al. · Journal of Controlled Release · 2020 · 61 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Albumin-Binding and Conventional PSMA Ligands in Combination with¹⁶¹Tb: Biodistribution, Dosimetry, and Preclinical Therapy

Viviane J. Tschan, Sarah D. Busslinger, Peter Bernhardt et al. · Journal of Nuclear Medicine · 2023 · 38 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

[225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA-617

Sarah D. Busslinger, Viviane J. Tschan, O.K. Richard et al. · Cancers · 2022 · 36 citations · Full text

Medicine, Oncology, Pharmacology +12

Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer

Viviane J. Tschan, Francesca Borgna, Sarah D. Busslinger et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2022 · 35 citations · Full text

Medicine, Oncology, Pharmacology +15

Terbium-149 production: a focus on yield and quality improvement towards preclinical application

Chiara Favaretto, Pascal V. Grundler, Zeynep Talip et al. · Scientific Reports · 2024 · 24 citations · Full text

Medicine, Nuclear Engineering, Nuclear Medicine +17